Can we improve the endoscopic resection of dysplastic lesions in colonic inflammatory bowel diseases?

Endoscopy 2025; 57(02): 156-157
DOI: 10.1055/a-2442-4918

Editorial

Referring to Angajala VT et al. doi: 10.1055/a-2369-7980

¹Gastroenterology, Mid Yorkshire Teaching NHS Trust, Wakefield, United Kingdom of Great Britain and Northern Ireland

²Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom of Great Britain and Northern Ireland (Ringgold ID: RIN4468)

References
1 King D, Reulen RC, Thomas T. et al. Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000–2018. Aliment Pharmacol Ther 2020; 51: 922-934
2 Lutgens MWMD, van Oijen MGH, van der Heijden GJMG. et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013; 19: 789-799
3 Angajala VT, Buxbaum JL, Phan J. et al. Comparative outcomes of endoscopic mucosal resection for laterally spreading lesions in inflammatory bowel disease. Endoscopy 2024;
4 Sidhu M, Shahidi N, Gupta S. et al. Outcomes of thermal ablation of the mucosal defect margin after endoscopic mucosal resection: a prospective, international, multicenter trial of 1000 large nonpedunculated colorectal polyps. Gastroenterology 2021; 161: 163-170.e3
5 Manta R, Zullo A, Telesca DA. et al. Endoscopic submucosal dissection for visible dysplasia treatment in ulcerative colitis patients: cases series and systematic review of literature. J Crohns Colitis 2021; 15: 165-168
6 Lightner AL, Vaidya P, Allende D. et al. Endoscopic submucosal dissection is safe and feasible, allowing for ongoing surveillance and organ preservation in patients with inflammatory bowel disease. Colorectal Dis 2021; 23: 2100-2107